MNKD · MannKind Corporation
$3.75
-1.05% last session
End-of-day data · close of 2026-09-11
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
29.7
Dividend yield
—
Beta
1.10
Avg volume
5M
Employees
1K
Daily Change %
-1.05%
5 Days Change
-2.96%
10 Days Change
-1.75%
30 Days Change
2.60%
60 Days Change
-3.67%
Month to Day Change
-1.01%
Year to Day Change
-30.51%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MNKD
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-11
Latest call per bank · past 12 months
Wells Fargo
Overweight$13.00
+243.0% vs priceRBC Capital
Sector Perform$4.75
+25.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-11 | Cantor Fitzgerald | Reiterates | Overweight | $8.00 |
| 2026-08-06 | Wells Fargo | Maintains | Overweight | $14.00 → $13.00 |
| 2026-07-30 | Wells Fargo | Maintains | Overweight | $11.00 → $14.00 |
| 2026-05-07 | RBC Capital | Maintains | Sector Perform | $3.50 → $4.75 |
| 2026-05-07 | Wells Fargo | Maintains | Overweight | $8.00 → $10.00 |
| 2026-05-07 | Mizuho | Maintains | Outperform | $8.00 → $7.00 |
| 2026-05-07 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10.00 |
| 2026-04-28 | Wells Fargo | Maintains | Overweight | $7.00 → $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.7% below the 50-day MA ($4.02).
- Price vs 200-day MA: Trading 9.4% below the 200-day MA ($4.14).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.28) and high ($6.21).
MNKD Price Chart
Loading chart for MNKD…
Fundamentals
About MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. It has a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.